Evaluating new technologies for diagnosing glaucoma and macular diseases
Novel Diagnostics for Ocular Structure
This study is testing new imaging technologies to see if they can better diagnose and monitor eye diseases like glaucoma and macular degeneration, while also looking for eye signs that might indicate Alzheimer's Disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Wills Eye Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT00286637 on ClinicalTrials.gov |
What this trial studies
This research aims to assess the effectiveness of optical coherence tomography (OCT) and other imaging devices in diagnosing and monitoring eye diseases such as glaucoma and age-related macular degeneration. The study includes various sub-studies, including cross-sectional and longitudinal analyses, to evaluate the performance and reproducibility of OCT measurements. Additionally, there is a sub-study focused on identifying ocular biomarkers for Alzheimer's Disease using high-resolution imaging technologies. The study is a continuation of previous work conducted at the New England Eye Center in collaboration with MIT.
Who should consider this trial
Good fit: Ideal candidates include healthy volunteers and individuals with age-related macular degeneration, diabetic retinopathy, or glaucoma.
Not a fit: Patients with conditions affecting visual field or retinal thickness unrelated to glaucoma, or those with significant ocular abnormalities, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier diagnosis and better monitoring of eye diseases, improving patient outcomes.
How similar studies have performed: Previous studies using OCT technology have shown promising results in imaging and diagnosing eye diseases, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ability to provide informed consent and to understand the study procedures * Healthy volunteers * Age related macular degeneration (AMD), diabetic retinopathy, central serous chorioretinopathy, and/or glaucoma or glaucoma suspects * (AD Sub-Study ONLY): Subjects diagnosed with AD or MCI. Exclusion Criteria: * Any medical treatment (e.g., chronic corticosteroid, hydroxychloroquine, chloroquine, thioridazine, canthaxanthine) or conditions that affect VF (e.g., stroke) and retinal thickness other than glaucoma. * Strabismus, nystagmus, or any condition that prevents fixation. * Presence of any media opacities that hinders clinical view of the fundus, and any intraocular non-glaucomatous abnormality * History of ocular trauma or intraocular surgery other than uncomplicated glaucoma interventions or cataract extraction at least 3 months previous to participating in the study.
Where this trial is running
Philadelphia, Pennsylvania
- Wills Eye Hospital — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Study coordinator: Taylor Harwood
- Email: tharwood@willseye.org
- Phone: 215-928-3197
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.